Fabry disease biomarkers in patients switched from enzyme replacement therapy to migalastat oral chaperone therapy

被引：0

作者：

Auray-Blais, Christiane ^{[1
,2
]}

Lavoie, Pamela ^{[1
,2
]}

Martineau, Tristan ^{[1
,2
]}

Ntumba, Georges Kabala ^{[1
,2
]}

Gamrani, Mohamed ^{[1
,2
]}

Khan, Aneal ^{[3
]}

Altarescu, Gheona ^{[4
]}

Lehman, Anna ^{[5
]}

Goker-Alpan, Ozlem ^{[6
]}

Nowak, Albina ^{[7
,8
]}

West, Michael L. ^{[9
]}

Bichet, Daniel G. ^{[10
,11
]}

机构：

[1] Univ Sherbrooke, Ctr Rech CIUSSS, Dept Pediat, Div Med Genet, 3001,12th Ave North, Sherbrooke, PQ J1H 5N4, Canada

[2] Univ Sherbrooke, Estrie CHUS, 3001,12th Ave North, Sherbrooke, PQ J1H 5N4, Canada

[3] Univ Calgary, Cumming Sch Med, 3330 Hosp Dr NW, Calgary, AB T2N 4N1, Canada

[4] Shaare Zedek Med Ctr, Shmuel Hans Beyth St 12, IL-9103102 Jerusalem, Israel

[5] Univ British Columbia, Vancouver Gen Hosp, Dept Med Genet, 899 W 12th Ave, Vancouver, BC V5Z 1M9, Canada

[6] Lysosomal & Rare Disorders Res & Treatment Ctr LDR, 3702 Pender Dr STE 170, Fairfax, VA 22030 USA

[7] Univ Hosp Zurich, Dept Endocrinol & Clin Nutr, Ramistr 100, CH-8091 Zurich, Switzerland

[8] Univ Zurich, Ramistr 100, CH-8091 Zurich, Switzerland

[9] Dalhousie Univ, QE II Health Sci Ctr, Dept Med, Div Nephrol, 1276 South Pk St, Halifax, NS B3H 2Y9, Canada

[10] Univ Montreal, 5400 Boul Gouin O, Montreal, PQ H4J 1C5, Canada

[11] Hop Sacre Coeur Montreal, Res Ctr, Nephrol Serv, 5400 Boul Gouin O, Montreal, PQ H4J 1C5, Canada

来源：

BIOANALYSIS | 2023年 / 15卷 / 23期

关键词：

analogues; biomarkers; Fabry disease; globotriaosylceramide; globotriaosylsphingosine; migalastat; treatment switch; MULTIPLEX ANALYSIS; GB(3) ISOFORMS; AMENABILITY; PHENOTYPE; CHILDREN; PLASMA;

D O I：

10.4155/bio-2023-0160

中图分类号：

Q5 [生物化学];

学科分类号：

071010 ; 081704 ;

摘要：

Background: A biomarker profile was evaluated longitudinally in patients with Fabry disease switched from enzyme replacement therapy (ERT) to migalastat. Methods: Sixteen Gb3 isoforms and eight lyso-Gb3 analogues were analyzed in plasma and urine by LC-MS/MS at baseline and at three different time points in naive participants and participants switching from either agalsidase alpha or beta to migalastat. Results: Twenty-nine adult participants were recruited internationally (seven centers). The Mainz Severity Score Index and mean biomarker levels remained stable (p >= 0.05) over a minimum of 12 months compared with baseline following the treatment switch. Conclusion: In this cohort of patients with Fabry disease with amenable mutations, in the short term, a switch from ERT to migalastat did not have a marked effect on the average biomarker profile. [GRAPHICS]

引用

页码：1421 / 1437

页数：17

共 50 条

[1] Fabry Disease: Switch from Enzyme Replacement Therapy to Oral Chaperone Migalastat: What Do We Know Today?
Perretta, Fernando
Jaurretche, Sebastian
HEALTHCARE, 2023, 11 (04)
[2] Diurnal Variation of Urinary Fabry Disease Biomarkers during Enzyme Replacement Therapy Cycles
Boutin, Michel
Lavoie, Pamela
Menkovic, Iskren
Toupin, Amanda
Abaoui, Mona
Elidrissi-Elawad, Maha
Arthus, Marie-Francoise
Fortier, Carole
Menard, Claudia
Maranda, Bruno
Bichet, Daniel G.
Auray-Blais, Christiane
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2020, 21 (17) : 1 - 14
[3] Impact of enzyme replacement therapy and migalastat on disease progression in females with fabry disease
Lenders, Malte
Nowak, Albina
Cybulla, Markus
Kaufeld, Jessica
Koehn, Anja Friederike
Muschol, Nicole Maria
Kurschat, Christine
Brand, Eva
ORPHANET JOURNAL OF RARE DISEASES, 2025, 20 (01)
[4] Impact of enzyme replacement therapy and migalastat on left atrial strain and cardiomyopathy in patients with Fabry disease
Pogoda, Christian
Brand, Stefan-Martin
Duning, Thomas
Schmidt-Pogoda, Antje
Sindermann, Juergen
Lenders, Malte
Brand, Eva
FRONTIERS IN CARDIOVASCULAR MEDICINE, 2023, 10
[5] A review and recommendations for oral chaperone therapy in adult patients with Fabry disease
Nowicki, Michal
Bazan-Socha, Stanislawa
Blazejewska-Hyzorek, Beata
Klopotowski, Mariusz M.
Komar, Monika
Kusztal, Mariusz A.
Liberek, Tomasz
Malyszko, Jolanta
Mizia-Stec, Katarzyna
Oko-Sarnowska, Zofia
Pawlaczyk, Krzysztof
Podolec, Piotr
Slawek, Jaroslaw
ORPHANET JOURNAL OF RARE DISEASES, 2024, 19 (01)
[6] Chaperone Therapy in Fabry Disease
Weidemann, Frank
Jovanovic, Ana
Herrmann, Ken
Vardarli, Irfan
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2022, 23 (03)
[7] Reduction of elevated plasma globotriaosylsphingosine in patients with classic Fabry disease following enzyme replacement therapy
van Breemen, Marielle J.
Rombach, Saskia M.
Dekker, Nick
Poorthuis, Ben J.
Linthorst, Gabor E.
Zwinderman, Aeilko H.
Breunig, Frank
Wanner, Christoph
Aerts, Johannes M.
Hollak, Carla E.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE, 2011, 1812 (01): : 70 - 76
[8] Enzyme replacement therapy of fabry disease
Joe T. R. Clarke
R. Mark Iwanochko
Molecular Neurobiology, 2005, 32 : 43 - 50
[9] Enzyme replacement therapy of Fabry disease
Clarke, JTR
Iwanochko, RM
MOLECULAR NEUROBIOLOGY, 2005, 32 (01) : 43 - 50
[10] Enzyme replacement therapy in Fabry disease
Grundmann, F.
Benzing, T.
Kurschat, C.
NEPHROLOGE, 2015, 10 (03): : 207 - 213

← 1 2 3 4 5 →